A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil

Cancer Investigation

Volumn 17, Issue 8, 1999, Pages 586-593

  Anderson, Norwood ^a   Lokich, Jacob ^a   Moore, Cherie ^a   Bern, Murray ^a   Coco, Frank ^a  

^a Cancer Center of Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; IRINOTECAN; MITOMYCIN C; SPARFOSIC ACID; TIOGUANINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032746202     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032844     Document Type: Article

References (33)

1. Erlichman C, Fine S, Wong A. et al: A randomized trial of fluorouracil with folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988.
2. Petrelli N, Douglass H, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989.
3. Poon M, O'Connell M, Moertel M, et al: Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7:1407-1418, 1989.
4. Petrelli N, Herrera L, Rustum Y, et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987.
5. Valone F, Friedman M, Wittlinger P, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989.
6. Poon M, O'Connell M, Wieand H, et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991.
7. Lokich J, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981.
8. Hansen R, Quebbeman E, Ausman R, et al: Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. J Surg Oncol 40:177-181, 1989.
9. Wade J, Herbst S, Greenberg A: Prolonged venous infusion of 5-fluorouracil for metastatic colon cancer-a follow-up report [abstract]. Proc Am Soc Clin Oncol 7:94, 1988.
10. Belt R, Davidner M, Myron M, et al: Continuous low-dose 5-fluorouracil for adenocarcinoma: confirmation of activity [abstract]. Proc Am Soc Clin Oncol 4:90, 1985.
11. Lokich J, Ahlgren J, Gullo J, et al: A prospective randomized comparison of infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989.
12. Lokich J, Ahlgren J, Gullo J, et al: A prospective randomized study of continuous infusion 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer 67:14-19, 1991.
13. Leichman C, Fleming R, Muggia F, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995.
14. Hansen R, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996.
15. Rinaldi D, Burris H, Dorr F, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995.
16. Cunningham D, Zalcberg J, Smith I, et al: "Tomudex" (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol 7:179-182, 1996.
17. Clarke S, Hanwell J, deBoer M, et al: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14:1495-1503, 1996.
18. Jackman A, Calvert A: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871-881, 1995.
19. Baccanari D, Davis S, Knick V, et al: 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 90:11064-11068, 1993.
20. Spector T, Harrington J, Porter D: 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem Pharmacol 46:2243-2248, 1993.
21. Rowinsky E, Baker S, Spector T, et al: Early clinical evaluation of the dihydropyrimidine dehydrogenase inhibitor 776C85 and oral 5-fluorouracil [abstract]. Cancer Invest 14(Suppl. 1):39, 1996.
22. Burris H, Von Hoff D, Ratain M, et al: Initial phase I trial of dihydropyrimidine dehydrogenase inactivator 5-ethynyluracil (776C85) plus 5-fluorouracil (5-FU) [abstract]. Ann Oncol 7(Suppl. 1):29, 1996.
23. Rothenberg M, Eckardt J, Juhn J, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996.
24. Shimada Y, Yooshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993.
25. Rougier P, Bugat R: CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 23(Suppl. 3):34-41, 1996.
26. Doll D, Weiss R, Issell B: Mitomycin: ten years after approval for marketing. J Clin Oncol 3:276-286, 1985.
27. Livingstone R, Carter S: Single Agents in Cancer Chemotherapy, New York, IFI/Plenum Press, 1970.
28. Lokich J, Perri J, Fine N, et al: Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule. Am J Clin Oncol 5:443-447, 1982.
29. Anderson N, Lokich J, Moore C. et al: Infusional mitomycin C (MMC) for treatment of measurable colorectal carcinoma (CRC) resistant to 5-fluorouracil (FU) [abstract]. Proc Am Soc Clin Oncol 11:191, 1992.
30. Benvenuto J, Anderson R, Kerkof K, et al: Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 38:1914-1918, 1981.
31. Bern M, Lokich J, Wallach S, et al: Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 112:423-428, 1990.
32. Poplin E, LoRusson P, Lokich J, et al: Randomized clinical trial of mitomycin C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33:415-419, 1994.
33. Ardalan B, Restrepo A, Deng Z, et al: Phase I-II trial of high dose 24-hour infusion of fluorodeoxyuridine (FUdR) in patients with colorectal cancers (previously failed 5-fluorouracil) [abstract]. Proc Am Soc Clin Oncol 15:202, 1996.